Sagimet Biosciences Financial Results
Sagimet Biosciences reported third quarter 2026 financial results and provided a corporate update on its Phase 3 AURORA clinical trial for denifanstat in moderate to severe acne. The company highlighted a pro forma cash position of $356 million following a $115 million equity financing in October, which is expected to fund operations through mid-2029.
“Building on the positive Phase 3 results from our license partner Ascletis, we have initiated our pivotal U.S. AURORA Phase 3 clinical trial. With our October equity financing, we are well positioned to fund our programs through mid-2029, including the anticipated Phase 3 denifanstat data readout and the potential submission of an NDA.”
David Happel, Chief Executive Officer